48 results on '"Savage, Greg"'
Search Results
2. A comparison of machine learning based‐composite cognitive test scores to track cognitive decline in early stages of Alzheimer’s disease dementia: ADOPIC study
3. Empirically derived composite cognitive test scores to predict preclinical and clinical stages of Alzheimer’s disease
4. AU‐ARROW (Australia)
5. The effects of mesial temporal tau in Ab‐negative cognitively normal older adults
6. P4-485: SPON1 IS ASSOCIATED WITH Aβ-AMYLOID AND APOE ε4 RELATED COGNITIVE DECLINE IN COGNITIVELY NORMAL ADULTS
7. O4‐09‐01: COMPARISON OF THE NATURAL HISTORY OF NEOCORTICAL Aβ‐AMYLOID, HIPPOCAMPAL VOLUME AND PACC IN SPORADIC AD
8. Features of Successful and Unsuccessful Collaborative Memory Conversations in Long‐Married Couples
9. Strategic value‐directed learning and memory in Alzheimer's disease and behavioural‐variant frontotemporal dementia
10. DIAGNOSTIC AND PROGNOSTIC POWER OF FLUID AND NEUROIMAGING MARKERS OF PATHOLOGY AND NEURODEGENERATION: THE ALZHEIMER'S IMAGING, BIOMARKERS, AND LIFESTYLE (AIBL) STUDY OF AGEING EXPERIENCE
11. REFINING THE NATURAL HISTORY OF GLOBAL AND REGIONAL Aβ-AMYLOID DEPOSITION IN SPORADIC ALZHEIMER’S DISEASE
12. COGNITIVE SUPER-AGING VERSUS TYPICAL AGING IN COMMUNITY-DWELLING OLDER ADULTS: LONGITUDINAL TRAJECTORIES IN GLOBAL CORTICAL THICKNESS OVER SIX YEARS
13. P4-288: TAU, aß and Cognition in Healthy Elderly: Preliminary Data From the Aibl Cohort
14. O3-13-02: CHARACTERIZING DYNAMIC PROPERTIES OF RETINAL VESSELS IN ALZHEIMER'S DISEASE
15. P2‐250: NOVEL STATISTICALLY‐DERIVED COMPOSITE MEASURES FOR ASSESSING THE EFFICACY OF DISEASE‐MODIFYING THERAPIES IN PRODROMAL AD TRIALS: AN AIPL STUDY
16. O3-06-05: LONGITUDINAL COGNITIVE DECLINE IN THE AIPL COHORT: THE ROLE OF APOE ɛ4 STATUS
17. P4‐164: QUALITATIVE THEMATIC ANALYSIS OF SUBJECTIVE MEMORY COMPLAINTS IN THE HEALTHY ELDERLY AND INDIVIDUALS WITH MCI
18. O1-06-01: THE ASSOCIATION BETWEEN AMYLOID BURDEN AND SUB-CLINICAL DEPRESSION IN HEALTHY OLDER ADULTS
19. Predicting Alzheimer disease with β‐amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing
20. O1-04-02: Beta-amyloid and cognitive change: Examining the preclinical and prodromal stages of Alzheimer's disease
21. P2-245: Cognitive consequences of high beta-amyloid levels in people with mild cognitive impairment and healthy older adults: Implications for early detection of Alzheimer's disease
22. P1-152: Dropout and its effect on the AIBL study
23. P1-150: Change in cognition over 36 months in relation to blood biomarkers
24. P2-267: Neuropsychological predictors of autobiographical memory impairment in mild cognitive impairment (MCI)
25. P4-217: Association of BMI and change in BMI with cognitive function, change in cognitive function and conversion to Alzheimer's disease
26. P2-266: Genetic algorithm with logistic regression for Alzheimer's disease diagnosis and prognosis
27. P3-223: Clinical utility of the cogstate brief battery in Alzheimer's disease-related memory impairment
28. P3-277: The Australian Imaging, Biomarkers and Lifestyle-Rate of Change sub-study (AIBL-ROCS): Rationale, design, acceptability and pilot data for the first three months of assessment
29. O4-08-05: Healthy older adults in the AIBL cohort at risk for cognitive decline
30. O3-02-01: Subjective memory complainers in the AIBL cohort: Hypervigilance amongst the worried well, or individuals at increased risk of Alzheimer's disease?
31. P2-178: Findings from the first 18-month follow up of the Australian Imaging Biomarkers and Lifestyle (AIBL) cohort
32. P3‐134: Normative data from the AIBL study: Language, visuoconstruction, and executive functioning in a large healthy elderly cohort
33. O4-05-06: Neuropsychological performance and the e4 and e2 alleles: Findings from the first phase of the australian imaging, biomarker and lifestyle (AIBL) flagship study of ageing
34. P1-045: The AIBL study: Baseline data from a multicenter, prospective longitudinal study of ageing in 1,100 volunteers
35. IC-P-022: The bimodality of healthy ageing: How do the differing profiles of healthy controls compare to patients with mild cognitive impairment?
36. P3-106: The bimodality of healthy ageing: How do the differing profiles of healthy controls compare to patients with mild cognitive impairment?
37. IC‐P‐013: The AIBL study: Baseline data from a multicenter, prospective longitudinal study of ageing in 1,100 volunteers
38. Memory profiling in mild cognitive impairment: Can we determine risk for Alzheimer's disease?
39. P1-153: The relationship between olfactory identification and memory and Abeta burden in Alzheimer's disease, mild cognitive impairment and healthy aging: A PIB-PET study
40. P2-006: Baseline data from a multi-centre, prospective longitudinal study of ageing in 1000 volunteers (the AIBL study)
41. O1-04-03: Amyloid burden in ageing subjects with and without cognitive decline
42. O1-04-06: Correlation of memory dysfunction and amyloid burden in mild cognitive impairment
43. P-092: Nicotinic receptors are not responsible for improved cognitive performance by galantamine in early Alzheimer's disease: A 2-[18 F]f-a-85380 PET study
44. P-032: Differentiation between Alzheimer's disease patients and healthy controls is not possible with 2-[18 F]F-A-85380 pet imaging of nicotinic receptors
45. IC–P–084: Nicotinic receptor upregulation and the cognitive effects of galantamine in Alzheimer's disease: A human in vivo study using [18F]F–A–85380 PET
46. P2-371: Nicotinic receptor upregulation and the cognitive effects of galantamine in Alzheimer's disease: A human in vivo study using [18 F]F-A-85380 PET
47. O3-06-07: C-11 PIB PET amyloid imaging in aging and dementia
48. IC-P-022: C-11 PIB PET amyloid imaging in ageing and dementia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.